Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Quince Therapeutics, Inc. incurred credit facility of EUR 30,000,000 unsecured credit facility with European Investment Bank at 9.00% per annum maturing August 11, 2026.
- Instrument
- credit facility
- Principal
- EUR 30,000,000 unsecured credit facility
- Counterparty
- European Investment Bank
- Rate
- 9.00% per annum
- Maturity
- August 11, 2026
- Event
- incurrence
Exact text from the filing
the “Quince Parties”), have agreed to guarantee the obligations of EryDel S.p.A, a company with shares incorporated under the laws of Italy (“EryDel”), in respect of a EUR 30,000,000 unsecured credit facility (the “EIB Facility”) evidenced by the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Luca Benatti was appointed as Director at Quince Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Quince Therapeutics, Inc. completed an acquisition involving EryDel S.p.A for 6,525,315 shares of common stock (closed 2023-10-20).
- Action
- acquisition
- Counterparty
- EryDel S.p.A
- Consideration
- 6,525,315 shares of common stock
- Closing
- 2023-10-20
Exact text from the filing
company solely in its capacity as the representative, agent and attorney-in-fact of the EryDel Shareholders. Pursuant to the terms of the Purchase Agreement, the Company issued 6,525,315 shares of common stock of the Company to the EryDel Shareholders, resulting in the EryDel Shareholders owning approximately 15.2% of the outstanding common stock of the Company.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Quince Therapeutics, Inc. entered into Finance Contract with European Investment Bank valued at EUR 30,000,000 (effective 2023-10-20).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- European Investment Bank
- Value
- EUR 30,000,000
- Effective
- 2023-10-20
Exact text from the filing
the Finance Contract, dated as of July 24, 2020 (the “Existing Finance Contract” and, as amended by the Amendment, the “Amended Finance Contract”), by and between EryDel, as borrower, and the European Investment Bank, as lender (the “Lender”), by entering into (i) an Accession, Amendment and Restatement Agreement, dated as of October 20, 2023 (the “Amendment”), which amends and restates the Existing Finance Contract and joins each Quince Party thereto as a guarantor of the obligations of EryDel thereunder, and (ii) an Autonomous First Demand Guarantee ( Garanzia Autonoma a Prima Richiesta ) by each Quince Party respectively in favor of the Lender (collectively, the “Guarantees”).
View on SEC.gov